COVID-19, virus identified
Conditions
Interventions
This is a cross-sectional study in which male and female individuals suspected of being infected by SARS-CoV2 will be recruited into 4 groups: a) 25-60 years old with mild/moderate (38 indivíduos) ver
2) serum biochemical profile
3) immunophenotypical analysis of blood B and T lymphocytes and NK cells
4) repertoire of immunoglobulins
4) DNA methylation
5) composition of gut microbiota.
V03.175.500
Sponsors
Universidade Federal de Minas Gerais (UFMG)
Merck Sharp & Dohme Farmacêutica Ltda
Instituto de Pesquisa Rene Rachou - Fundação Oswaldo Cruz
Instituto de Infectologia Emílio Ribas
Universidade Federal de Juiz de Fora - Governador Valadares
Eligibility
Age
20 Years to No maximum
Inclusion criteria
Inclusion criteria: All indivíduals that are tested positive for SARS-Cov2 by PCR . Above 20 years of age. Negative individuals will be recruited as controls. Both genders
Exclusion criteria
Exclusion criteria: Individuals bellow 20 years of age
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Expected Outcome 1: To evaluate the phenotype of T and B lymphocytes and NK cells by flow cytometry. It is expected that individuals with severe COVID-19 will have increased frequencies of lymphocytes and NK cells expressing markers of cellular senescence (PD1, LAG3, CD28, CD160, CD127, TIGIT);Expected Outcome 2: To evaluate the inflammatory profile (inflammaging) of individuals using the Luminex platform to measure serum cytokines/chemokines. It is expected that individuals with severe COVID-19 will have a more inflammatory profile when compared to individuals with mild/moderate disease or control individuals;Expected Outcome 3: To analyse the immunoglobulin (Ig) repertoire of B cells from individuals using the RNA sequencing of activated B cells. It is expected that B cell repertoire of individuals with severe COVID-19 will be more oligoclonal (less variability in the VH regions of Ig) than the ones from individuals with mild/moderate disease or control individuals;Expected Outcome 4: To analyse the microbiota composition in fecal samples of individuals using next generation sequencing methodology. It is expected that individuals with severe COVID-19 will have disbiosis (more inflammatory profile of bacteria in their microbiota) when compared to individuals with mild/moderate disease or control individuals;Expected Outcome 5: To analyse the DNA methylation in leucocytes to evaluate the biological age of individuals using the Illumina Platform. It is expected that individuals with severe COVID-19 would have an accelerated cellular senescence (higher methylation index) when compared with individuals with mild/moderate disease or with control individuals;Expected Outcome 6: Correlate serum basic biochemical markers of inflammation and of COVID-19 (to create an index) of individuals with the information on the other inflammatory and clinical parameters to find easily-accessible biomarkers of disease outcome. It is expected that the detailed analysis of immunological, | — |
Secondary
| Measure | Time frame |
|---|---|
| Expected Outcome 7: Building the database with all data collected. It is expected that this database can be used in the future for other studies on COVID-19, other infeccions and also on immunosenescence;Expected Outcome 8: To analyse the impact of several comorbidities in the immunosenescence profile and in COVID-19 outcome. It is expected that chronic inflammatory diseases (such as hypertension, pneumopathies, obesity, diabetes) will impact in immunosenesce and therefore in the outcome of COVID-19;Outcome found 7: A comprehensive database has been created, providing a valuable source for future studies on COVID-19, other infections and immunosenescence;Outcome found 8: Comorbidities such as hypertension, lung diseases, obesity and diabetes have been shown to have a significant impact on the immunosenescence profile, affecting the outcome of COVID-19 and contributing to the severity of the inflammatory response | — |
Countries
Brazil
Contacts
Public ContactAna Maria Faria
Universidade Federal de Minas Gerais (UFMG)
Outcome results
None listed